Zuventus Healthcare Limited has issued a formal clarification to counter false and misleading communications about its future, positioning the move as essential to protecting confidence in an innovation-led healthcare business.
The company categorically denied rumours of closure or rebranding, stating that there has been no shutdown, suspension, or transfer of business assets. Zuventus confirmed that its field staff continues to operate at full strength across India, underscoring uninterrupted execution across sales, distribution, and medical outreach—critical engines for scaling healthcare solutions in a competitive market.
Addressing speculation linking it to Zorvia Healthcare Limited, Zuventus clarified that it has no association or affiliation with any such entity, calling the claims inaccurate and misleading. The company said it is actively pursuing appropriate legal remedies to protect its goodwill and stakeholder trust, an increasingly important factor for healthcare brands operating at scale.
Founded in 2002, Zuventus is a subsidiary of Emcure Pharmaceuticals, listed on the Bombay Stock Exchange and the National Stock Exchange. Backed by robust manufacturing standards and a growing field force, Zuventus focuses on science-driven, patient-centric innovation across branded generics.
Its diversified portfolio spans cardiology, diabetology, gastroenterology, orthopaedics, pain management, and nutraceuticals addressing both chronic and acute conditions with an emphasis on quality and affordability. The company reiterated its responsibility to develop, manufacture, and market accessible medicines while building long-term trust with doctors, partners, and patients nationwide.
